Safety and efficacy of apixaban in patients with glomerulonephritis and nephrotic syndrome: a prospective longitudinal cohort study
Aim. Assessment of the efficacy and safety of apixaban in preventing thromboembolic complications in patients with nephrotic syndrome caused by primary glomerulonephritis. Materials and methods. We conducted a prospective longitudinal cohort study involving 125 patients with glomerulonephritis an...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Zaporizhzhia State Medical and Pharmaceutical University
2025-03-01
|
| Series: | Сучасні медичні технології |
| Subjects: | |
| Online Access: | https://medtech.mphu.edu.ua/article/view/320766/315341 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849768575156355072 |
|---|---|
| author | I. S. Mykhaloiko R. I. Yatsyshyn I. O. Dudar O. I. Hotsaniuk H. M. Kuryliv |
| author_facet | I. S. Mykhaloiko R. I. Yatsyshyn I. O. Dudar O. I. Hotsaniuk H. M. Kuryliv |
| author_sort | I. S. Mykhaloiko |
| collection | DOAJ |
| description | Aim. Assessment of the efficacy and safety of apixaban in preventing thromboembolic complications in patients with nephrotic syndrome caused by primary glomerulonephritis.
Materials and methods. We conducted a prospective longitudinal cohort study involving 125 patients with glomerulonephritis and nephrotic syndrome. According to the inclusion criteria, patients had to be over 18 years of age, diagnosed with nephrotic syndrome within the last month, and have an estimated glomerular filtration rate greater than 60 ml/min/1.73 m². The study population was divided into two cohorts for comparison: one group (62 patients) received prophylactic anticoagulation with warfarin, while the other group (63 patients) was administered apixaban at a dose of 5 mg twice daily. The observation period was 6 months.
Results. During the observation period, no thromboembolic events were reported in either group, indicating the effectiveness of both treatments. However, minor bleeding events were significantly more frequent in the warfarin group than in the apixaban group (p = 0.003). These findings suggest that apixaban is associated with a lower risk of bleeding while maintaining effective thromboembolic prevention.
Conclusions. This study highlights that apixaban is a potentially better alternative to warfarin for thromboprophylaxis in patients with nephrotic syndrome and glomerulonephritis, particularly in those at high thromboembolic risk. Further randomized controlled trials are recommended to confirm these findings and optimize anticoagulation strategies for this population. |
| format | Article |
| id | doaj-art-2d93f57956ce41c2b9ee13782cf4fcdc |
| institution | DOAJ |
| issn | 2072-9367 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Zaporizhzhia State Medical and Pharmaceutical University |
| record_format | Article |
| series | Сучасні медичні технології |
| spelling | doaj-art-2d93f57956ce41c2b9ee13782cf4fcdc2025-08-20T03:03:45ZengZaporizhzhia State Medical and Pharmaceutical UniversityСучасні медичні технології2072-93672025-03-014145https://doi.org/10.14739/mmt.2025.1.320766Safety and efficacy of apixaban in patients with glomerulonephritis and nephrotic syndrome: a prospective longitudinal cohort studyI. S. Mykhaloiko0https://orcid.org/0000-0002-7943-9029R. I. Yatsyshyn1https://orcid.org/0000-0003-1262-5609I. O. Dudar2https://orcid.org/0000-0002-4372-8240O. I. Hotsaniuk3https://orcid.org/0000-0001-9691-7419H. M. Kuryliv4https://orcid.org/0000-0003-1426-1343Ivano-Frankivsk National Medical University, UkraineIvano-Frankivsk National Medical University, UkraineBogomolets National Medical University, Kyiv, UkraineIvano-Frankivsk National Medical University, UkraineIvano-Frankivsk National Medical University, UkraineAim. Assessment of the efficacy and safety of apixaban in preventing thromboembolic complications in patients with nephrotic syndrome caused by primary glomerulonephritis. Materials and methods. We conducted a prospective longitudinal cohort study involving 125 patients with glomerulonephritis and nephrotic syndrome. According to the inclusion criteria, patients had to be over 18 years of age, diagnosed with nephrotic syndrome within the last month, and have an estimated glomerular filtration rate greater than 60 ml/min/1.73 m². The study population was divided into two cohorts for comparison: one group (62 patients) received prophylactic anticoagulation with warfarin, while the other group (63 patients) was administered apixaban at a dose of 5 mg twice daily. The observation period was 6 months. Results. During the observation period, no thromboembolic events were reported in either group, indicating the effectiveness of both treatments. However, minor bleeding events were significantly more frequent in the warfarin group than in the apixaban group (p = 0.003). These findings suggest that apixaban is associated with a lower risk of bleeding while maintaining effective thromboembolic prevention. Conclusions. This study highlights that apixaban is a potentially better alternative to warfarin for thromboprophylaxis in patients with nephrotic syndrome and glomerulonephritis, particularly in those at high thromboembolic risk. Further randomized controlled trials are recommended to confirm these findings and optimize anticoagulation strategies for this population.https://medtech.mphu.edu.ua/article/view/320766/315341apixabannephrotic syndromeglomerulonephritisthromboembolismanticoagulationwarfarinbleeding complications |
| spellingShingle | I. S. Mykhaloiko R. I. Yatsyshyn I. O. Dudar O. I. Hotsaniuk H. M. Kuryliv Safety and efficacy of apixaban in patients with glomerulonephritis and nephrotic syndrome: a prospective longitudinal cohort study Сучасні медичні технології apixaban nephrotic syndrome glomerulonephritis thromboembolism anticoagulation warfarin bleeding complications |
| title | Safety and efficacy of apixaban in patients with glomerulonephritis and nephrotic syndrome: a prospective longitudinal cohort study |
| title_full | Safety and efficacy of apixaban in patients with glomerulonephritis and nephrotic syndrome: a prospective longitudinal cohort study |
| title_fullStr | Safety and efficacy of apixaban in patients with glomerulonephritis and nephrotic syndrome: a prospective longitudinal cohort study |
| title_full_unstemmed | Safety and efficacy of apixaban in patients with glomerulonephritis and nephrotic syndrome: a prospective longitudinal cohort study |
| title_short | Safety and efficacy of apixaban in patients with glomerulonephritis and nephrotic syndrome: a prospective longitudinal cohort study |
| title_sort | safety and efficacy of apixaban in patients with glomerulonephritis and nephrotic syndrome a prospective longitudinal cohort study |
| topic | apixaban nephrotic syndrome glomerulonephritis thromboembolism anticoagulation warfarin bleeding complications |
| url | https://medtech.mphu.edu.ua/article/view/320766/315341 |
| work_keys_str_mv | AT ismykhaloiko safetyandefficacyofapixabaninpatientswithglomerulonephritisandnephroticsyndromeaprospectivelongitudinalcohortstudy AT riyatsyshyn safetyandefficacyofapixabaninpatientswithglomerulonephritisandnephroticsyndromeaprospectivelongitudinalcohortstudy AT iodudar safetyandefficacyofapixabaninpatientswithglomerulonephritisandnephroticsyndromeaprospectivelongitudinalcohortstudy AT oihotsaniuk safetyandefficacyofapixabaninpatientswithglomerulonephritisandnephroticsyndromeaprospectivelongitudinalcohortstudy AT hmkuryliv safetyandefficacyofapixabaninpatientswithglomerulonephritisandnephroticsyndromeaprospectivelongitudinalcohortstudy |